DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Top Ranked Growth Stocks to Buy for December 17th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 17th
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Why Is DaVita HealthCare (DVA) Up 2.9% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Option Care Health (BIOS) Surges: Stock Moves 7.3% Higher
by Zacks Equity Research
Option Care Health (BIOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Top Ranked Growth Stocks to Buy for December 5th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 5th:
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Samsung, Target and Davita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Samsung, Target and Davita
A Holiday-Shortened Global Week Ahead
by John Blank
This is going to be a short trading week in the USA. Chief Strategist John Blank doesn't see much in the way of market moving events. Here are Reuters' latest five world market themes, reordered into relative importance for equity traders.
The Zacks Analyst Blog Highlights: Amedisys, DaVita, Tenet and Hanger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, DaVita, Tenet and Hanger
The Zacks Analyst Blog Highlights: DaVita, Quanta Services, CRA International, NRG Energy and First American Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Quanta Services, CRA International, NRG Energy and First American Financial
4 Healthcare Stocks to Gain From Stellar Q3 Earnings
by Manaswita Ghosh Dutta
Prominent activities in the healthcare sector are pushing the sector ahead this quarter.
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd
Shrug Off Market Gyrations With These Top 5 Value Picks
by Nalak Das
A strong rally is unlikely for as long as this trade conflict continues. However, the downside potential will be limited owing to U.S. economic strength.
Why DaVita HealthCare (DVA) Might be Well Poised for a Surge
by Zacks Equity Research
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for November 12th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.
DaVita HealthCare (DVA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 24.39% and 1.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the third quarter.
DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.